Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biomedicines
Autori principali: Li, Jielin, Pohl, Laura, Schüler, Julia, Korzeniewski, Nina, Reimold, Philipp, Kaczorowski, Adam, Hou, Weibin, Zschäbitz, Stefanie, Nientiedt, Cathleen, Jäger, Dirk, Hohenfellner, Markus, Duensing, Anette, Duensing, Stefan
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8227814/
https://ncbi.nlm.nih.gov/pubmed/34072926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines9060627
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi